 The largest experience published by Danzi and colleagues was a 554- patient observational study comparing the safety and efficacy of SHDB tirofiban in PCI patients to a cohort of PCI patients who received abciximab6. Patients were enrolled sequentially: the first 280 received abciximab and the subsequent 274 received HDB tirofiban. The incidence of major bleeding events or access site bleeding complications for patients treated with SHDB tirofiban was less than that seen with abciximab. Moreover, the point estimate of the incidence of in-hospital and 30-day major adverse cardiovascular events MACE in the SHDB tirofiban group was actually below that in the abciximab group 5.6 vs. 7.1; P0.65. This clinical experience suggests that SHDB tirofiban, administered at the time of PCI, is safe and can produce results similar to abciximab. 